Volume 25, Issue 115, September 2021

Development of nano-formulating dexamethasone for anterior uveitis treatment: A randomized clinical trial study

Mostafa Feghhi^1♦, Behzad Sharif Makhmalzadeh², Fereydoun Farrahi¹, Alinejat Sharafi¹, Ali Kasiri¹

¹Department of Ophthalmology, Faculty of Medicine, Infectious Ophthalmic Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
²Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

^♦Corresponding author
Department of Ophthalmology, Faculty of Medicine, Infectious Ophthalmic Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

ABSTRACT

Objective: To evaluate the efficiency of nano-formulating dexamethasone in the treatment of anterior uveitis. Methods: The present study is a randomized clinical trial study conducted on 20 patients with anterior uveitis referred to the Ophthalmology Department of Imam Khomeini Hospital, Ahvaz University of Medical Science from June 2019 to March 2020. Patients were divided into two groups randomly with 10 subjects in each group. One group of patients received micellar nanoparticle containing 0.1% dexamethasone (DEX) (the nanoparticle group) and another group received 0.1% DEX solution (the control group). In the 1st, 3rd, 7th, 14th, and 28th day of the treatment and second month after treatment, the patients were followed-up clinically. The number of visible cells in the anterior chamber are counted and graded on a scale of 0 to 4 based on the Standardization of Uveitis Nomenclature Working Group. Visual acuity, posterior adhesion, cell count of anterior chamber, flare, hypopyon, and intraocular pressure was compared between the two groups. Besides, the correlation between hypopyon and vision, the cell count in the anterior chamber and visual acuity, visual acuity and flare, visual acuity and posterior adhesion. Results: There was a difference in visual acuity, removal of posterior adhesion, cell count of anterior chamber, flare, improving hypopyon, intraocular pressure significantly between the nano DEX group and the control group (P<0.05). Conclusions: The use of 0.1% DEX nanoparticles can be quite effective in anterior uveitis treatment. Therefore, more controlled studies are needed to understand and recognize the effects of DEX nanoparticles in the treatment of uveitis.

Keywords: Uveitis; Nano-micellar compounds containing dexamethasone; Flare; Hypopyon

Medical Science, 2021, 25(115), 2440-2451

PDF